التفاصيل البيبلوغرافية
| العنوان: |
Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature. |
| المؤلفون: |
Chen, S.-W., Hwang, W.-S., Tsao, C.-J., Liu, H.-S., Huang, G.-C. |
| المصدر: |
Journal of Clinical Pharmacy & Therapeutics; Dec2005, Vol. 30 Issue 6, p623-625, 3p |
| مصطلحات موضوعية: |
CHRONIC myeloid leukemia, IRRADIATION, DRUG therapy, CHRONIC leukemia, MYELOID leukemia, PROTEIN-tyrosine kinases, PHARMACOLOGY |
| مستخلص: |
Therapeutic agents for chronic myeloid leukaemia (CML) in the chronic phase include hydroxyurea, interferon alpha, allogeneic stem cell transplantation and the tyrosine kinase inhibitor imatinib (STI 571, Gleevec). For elderly patients, oral hydroxyurea is suitable for the relief of symptoms caused by hyperleukocytosis, and splenic irradiation would be considered if abdominal discomfort or fullness induced by splenomegaly were present. Tumour lysis syndrome (TLS) is seldom seen in the treatment for CML, and TLS caused by hydroxyurea or splenic irradiation is rarely observed. Herein, we report an elderly CML patient who received treatment with hydroxyurea, allopurinol, hydration and splenic irradiation. After 3 days, acute TLS developed. Aggressive supportive treatment, including haemodialysis, stabilized the condition. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Pharmacy & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |